News – Page 994 – Endpoints News

Flailing Merrimack brings out the ax for another big cutback, lopping 60% of a shrinking crew as it hunts options

7 years ago

InCarda grabs a $42M round to back PoC study for their inhaled cardio drug

7 years ago

Eyes on neuro breakthroughs, newcomer Biomatics adds biotech vets and $300M with second fund

7 years ago

Voyager's shares sink after execs say FDA has reversed course on an accelerated filing for its gene therapy

7 years ago

AstraZeneca chief Pascal Soriot heralds the start of a 'period of sustained growth for years to come'

7 years ago

Eli Lilly sweeps the rest of the BACE work out of the pipeline following their latest major setback on Alzheimer’s

7 years ago

Shares of Bone Therapeutics dive on PhIII cell therapy failure; GSK-backed Sitryx inks discovery deal

7 years ago

Moment of truth looms for Nektar, Bristol-Myers with a major update to NKTR-214 combo — and the latest snapshot is ...

7 years ago

Bristol-Myers lays off the last 63 staffers at ZymoGenetics, shutters Seattle operations

7 years ago

A star drug in Mallinckrodt’s $1.2B Sucampo buyout flops in pivotal trial

7 years ago

Bound to the hip with Trump, ex-Celgene chief Bob Hugin gets whipped in New Jersey Senate race

7 years ago

The resurrection of LUM001: Mike Grey gets his drug back from Shire — along with $120M to gamble on PhIII trials

7 years ago

Foamix claims goal-winning success in twin pivotal studies for rosacea — shares spike

7 years ago

Dana-Farber team identifies new 'gene traffic control' targets in two rare, aggressive cancers

7 years ago

Centrexion eyes $70M-$80M in IPO with big plans for PhIII non-opioid painkiller

7 years ago

Amgen offers cash and milestones for Provention to take the lead on a celiac drug; Aveo's PhIII fails to impress, ...

7 years ago

Are more immuno-oncology buyouts on the menu at Eli Lilly’s executive suite?

7 years ago

OncoSec’s defense of weak preliminary Tavo data for PD-1 resistant melanoma can’t stop a rout

7 years ago

With its back against the wall, Regulus hands over its lead microRNA drug to Sanofi for a small down payment

7 years ago

Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster ...

7 years ago

Bargain sale continues: AstraZeneca offloads three respiratory drugs to Covis in $350M deal

7 years ago

Floundering in the wake of an FDA approval, Achaogen makes a second round of deep cuts to stay alive

7 years ago

After playing possum in I/O, Eli Lilly shows new signs of life with $40M-plus cash discovery deal for NextCure

7 years ago

Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use

7 years ago

First page Previous page 991 992 993994995 996 997 Next page Last page